Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis

Evidence Base ◽

Actual Clinical Practice ◽

The aim of this review was to study the evidence base for the efficacy and safety of the P2Y12 receptor blocker ticagrelor in combination with acetylsalicylic acid in patients with stable coronary artery disease and high and moderate risk of adverse cardiovascular events. Currently, the mortality rate of this category of patients remains high. Long-term dual antithrombotic therapy allows to improve the prognosis. Ticagrelor at a low dose (60 mg 2 times a day) in combination with acetylsalicylic acid in randomized clinical trials and an actual clinical practice has shown a beneficial effect on prognosis in stable coronary artery disease.

Physical activity and long-term prognosis in patients with stable coronary artery disease: How often, how intense, and how long?

European Journal of Preventive Cardiology ◽

10.1177/2047487319881238 ◽

2019 ◽

Vol 27 (4) ◽

pp. 422-425 ◽

Cited By ~ 2

Author(s):

Kazunori Shimada ◽

Miho Nishitani-Yokoyma ◽

Tetsuya Takahashi ◽

Hiroyuki Daida

Keyword(s):

Physical Activity ◽

Coronary Artery Disease ◽

Coronary Artery ◽

Artery Disease ◽

Long Term Prognosis

COLCHICINE IN STABLE CORONARY ARTERY DISEASE, A SYSTEMATIC REVIEW AND METANALYSIS OF RANDOMIZED CLINICAL TRIALS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(21)01538-2 ◽

2021 ◽

Vol 77 (18) ◽

pp. 179

Author(s):

Mahmoud El Iskandarani ◽

Islam Shatla ◽

Muhammad Khalid ◽

Timir Paul

Keyword(s):

Systematic Review ◽

Coronary Artery Disease ◽

Clinical Trials ◽

Coronary Artery ◽

Randomized Clinical Trials ◽

Exploring the potential of low-dose sulfasalazine in stable coronary artery disease patients: randomized, double-blind, placebo-controlled study

European Heart Journal - Cardiovascular Pharmacotherapy ◽

10.1093/ehjcvp/pvv021 ◽

2015 ◽

Vol 1 (4) ◽

pp. 214-216 ◽

Cited By ~ 3

Author(s):

Kanchan Vohra ◽

Pawan Krishan ◽

Sudhir Varma ◽

Harpreet Singh Kalra

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Low Dose ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

P1793Preprocedural neutrophil-lymphocyte ratio and long-term cardiac outcomes after percutaneous coronary intervention for stable coronary artery disease

European Heart Journal ◽

10.1093/eurheartj/ehx502.p1793 ◽

2017 ◽

Vol 38 (suppl_1) ◽

Author(s):

H. Wada ◽

T.D. Dohi ◽

K.M. Miyauchi ◽

S.D. Doi ◽

H.K. Konishi ◽

...

Keyword(s):

Coronary Artery Disease ◽

Percutaneous Coronary Intervention ◽

Coronary Artery ◽

Coronary Intervention ◽

Neutrophil Lymphocyte Ratio ◽

Cardiac Outcomes ◽

Percutaneous Coronary ◽

Reply to: “Comment on “Mean platelet volume and long-term cardiovascular outcomes in patients with stable coronary artery disease” ”

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.11.023 ◽

2019 ◽

Vol 280 ◽

pp. 195-196

Author(s):

Hideki Wada ◽

Tomotaka Dohi ◽

Katsumi Miyauchi ◽

Hiroyuki Daida

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Mean Platelet Volume ◽

Cardiovascular Outcomes ◽

Platelet Volume ◽

Hypertension and chronic kidney disease affect long-term outcomes in patients with stable coronary artery disease receiving percutaneous coronary intervention

Scientific Reports ◽

10.1038/s41598-018-35982-4 ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 2

Author(s):

Mao-Jen Lin ◽

Wen-Chieh Yang ◽

Chun-Yu Chen ◽

Chia-Chen Huang ◽

Hsun-Yang Chuang ◽

...

Keyword(s):

Coronary Artery Disease ◽

Chronic Kidney Disease ◽

Percutaneous Coronary Intervention ◽

Coronary Artery ◽

Coronary Intervention ◽

Long Term Outcomes ◽

Percutaneous Coronary ◽

Fixed-dose combination of ivabradine and metoprolol in a patient with stable coronary artery disease: a case report

Russian Journal of Cardiology ◽

10.15829/1560-4071-2021-4657 ◽

2021 ◽

Vol 26 (9) ◽

pp. 4657

Author(s):

A. M. Shimkevich

Keyword(s):

Coronary Artery Disease ◽

Case Report ◽

Clinical Practice ◽

Coronary Artery ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Actual Clinical Practice ◽

Dose Combination ◽

This article discusses a case of using fixed-dose combination of ivabradine/metoprolol in actual clinical practice.

Sex differences in clinical outcomes of patients with stable coronary artery disease after percutaneous coronary intervention

Current Pharmaceutical Design ◽

10.2174/1381612827666210303142901 ◽

2021 ◽

Vol 27 ◽

Author(s):

Emmanuel P. Vardas ◽

Evangelos Oikonomou ◽

Gerasimos Siasos ◽

Panagiotis Theofilis ◽

Polychronis Dilaveris ◽

...

Keyword(s):

Coronary Artery Disease ◽

Risk Factor ◽

Coronary Artery ◽

Independent Risk Factor ◽

Coronary Intervention ◽

Female Sex ◽

Percutaneous Coronary ◽

: Potential sex-related differences in the periprocedural and long-term postprocedural outcomes of coronary angioplasty in patients with stable coronary artery disease have been studied thoroughly over the last few decades, to determine whether female sex should be regarded as an independent risk factor that affects clinical outcomes. Based on a significant number of observational studies and meta-analyses, sex has not yet emerged as an independent risk factor for either mortality or major cardiac and cerebrovascular events, despite the fact that in the early 1980s, for several reasons, female sex was associated with unfavourable outcomes. Therefore, it remains debatable whether female sex should be considered as an independent risk factor for periprocedural and long-term bleeding events. The pharmacological and technological advancements that support current coronary angioplasty procedures, as well as the non-delayed treatment of coronary artery disease in females have certainly lessened the outcome differences between the two sexes. However, females show fluctuations in blood coagulability through their lifetime and higher prevalence of bleeding episodes associated with the antithrombotic treatment, following transcatheter coronary reperfusion interventions. In conclusion, the clinical results of percutaneous coronary intervention in patients with stable coronary artery disease, during the periprocedural and long-term postprocedural periods, appear to show no significant differences between the two sexes, except for bleeding rates, which seem to be higher in females, a difference that mandates further systematic research.